Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Citadel Advisors LLC reported a 6.00% stake in Acrivon Therapeutics, Inc. (Schedule 13G/A)
Event Mar 31, 2025 · Filed May 15, 2025
Citadel Advisors LLC reported a 6.00% stake in Acrivon Therapeutics, Inc., 1,895,519 shares, as a passive investor on Mar 31, 2025. Filed May 15, 2025 (Schedule 13G/A).
- Stake
- 6.00%
- Shares
- 1,895,519
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Citadel Advisors LLC | 6.00% | 1,895,519 |
| Citadel Advisors Holdings LP | 6.00% | 1,895,519 |
| Citadel GP LLC | 6.00% | 1,895,519 |
| Citadel Securities LLC | 0% | 99 |
| Citadel Securities Group LP | 0% | 99 |
| Citadel Securities GP LLC | 0% | 99 |
| Kenneth Griffin | 6.00% | 1,895,618 |
Source
Related
- Acrivon Therapeutics, Inc.
- Citadel Advisors LLC
- Acrivon Therapeutics, Inc. shareholders
- Schedule 13G/A · Citadel Advisors LLC · May 15, 2026
- Schedule 13G · Citadel Advisors LLC · Nov 21, 2025
- Schedule 13G/A · Citadel Advisors LLC · Nov 14, 2025
- Form 4 · Miller Mary · Oct 7, 2026
- Form 4 · Levin Michaela · Sep 2, 2026
- Form 4 · Blume-Jensen Peter · Aug 27, 2026
- Form 4 · Peterson Katharine · Aug 20, 2026
- Form 4 · Miller Mary · Aug 20, 2026